Pfizer Inc.’s stock tumbled 6% Friday, after the company said it would not move to a Phase 3 trial of a twice-daily formulation of a weight-loss drug after patients in an earlier study had a lot of ...
A digital therapeutic (DTx) that aims to treat negative symptoms of schizophrenia, like apathy and social withdrawal, has hit the target in a phase 3 trial. The smartphone-based CT-155 app, ...
Time Spectrum Analyzer, built on the newly upgraded UltraReal platform. This innovative instrument seamlessly integrates high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback